Efficacy of topical Bevacizumab in patients diagnosed with dry eye disease compared with conventional treatment

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171024002

Enrollment

Registered

2017-10-24

Start date

2017-05-18

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye disease Dryness of eye Keratoconjunctivitis Sicca eye dryness xeroma Bevacizumab

Interventions

Bevacizumab is a humanized monoclonal antibody for anti&#45

vascular endothelial growth factor (Anti&#45

VEGF). ,Artificial tears which are the standard of treatment in patients with dry eye disease

Active Comparator Drug,Active Comparator Drug

Topical Bevacizumab,Conventional method

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients from outpatient department of the Department of Ophthalmology, King Chulalongkorn Memorial Hospital 2. Patients diagnosed with dry eye disease aged 18 to 80 years old 3. Slit lamp examination Tear Break-Up Time (SLETBUT) <= 5 seconds 4. Patients who can regularly pay a visit as appointed

Exclusion criteria

Exclusion criteria: 1. Any structural abnormalities (such as eyelid trichiasis, entropion, and scarring) 2. The presence of pinguecula or pterygium 3. Active allergy or infection or inflammatory disease at the ocular surface unrelated to dry eye 4. Any inflammation or active structural change in the iris or anterior chamber 5. Glaucoma 6. Diabetes or other systemic, dermatologic, or neurologic diseases that affect the health of ocular surface 7. Use of any other topical medication other than artificial tears within the past month 8. Use of any systemic anti-inflammatory drugs or medication that may interfere with tear production, such as anti-anxiety, anti-depressive, and anti-histamine medications within 3 months 9. Previous punctal occlusion or eye surgery 10. A positive history of refractive surgery or contact lens wear 11. Hypertension that is unstable 12. History of any Bevacizumab contraindications, such as heart failure, gastrointestinal perforation, and pregnancy.

Design outcomes

Primary

Measure	Time frame
NIKBUT 1-week, 1-month, 3-month Slit-lamp examination test	—

Secondary

Measure	Time frame
OSDI 1-week, 1-month, 3-month Questionnaire,Shirmer's 1 test 1-week, 1-month, 3-month Fluorescein clearance timing,Grading ocular surface staining score 1-week, 1-month, 3-month Fluoresceine staining	—

Countries

Thailand

Contacts

Public ContactNgamjit Kasetsuwan

King Chulalongkorn Memorial Hospital

kanawatc@gmail.com0649944788

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026